Provided by Tiger Trade Technology Pte. Ltd.

CEL-SCI Corp

3.20
-0.2700-7.78%
Post-market: 3.200.00000.00%19:43 EDT
Volume:58.23K
Turnover:187.41K
Market Cap:27.07M
PE:-0.61
High:3.48
Open:3.40
Low:3.10
Close:3.47
52wk High:13.48
52wk Low:1.98
Shares:8.46M
Float Shares:6.64M
Volume Ratio:1.65
T/O Rate:0.88%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.2407
EPS(LYR):-6.2655
ROE:-212.12%
ROA:-59.90%
PB:2.43
PE(LYR):-0.51

Loading ...

CEL-SCI Q4 2025 EPS $(0.68) Vs $(3.25) Q4 2024

Benzinga
·
Feb 18

Press Release: CEL-SCI Reports Fiscal First Quarter 2026 Results

Dow Jones
·
Feb 18

CEL-SCI reports Q1 general and administrative expenses down 31% to USD 1.8 million

Reuters
·
Feb 18

Banco Bradesco Clarifies Agribusiness Growth Projections After CVM Inquiry

TIPRANKS
·
Feb 14

Press Release: ITAÚ UNIBANCO - Material Fact: Guidance 2026

Dow Jones
·
Feb 05

Geert R. Kersten, CEO, Reports Acquisition of CEL-SCI Corporation Common Shares

Reuters
·
Jan 26

Press Release: CEL-SCI Reports Fiscal 2025 Results

Dow Jones
·
Dec 29, 2025

CEL-SCI posts FY net operating loss of USD 24.8 million

Reuters
·
Dec 29, 2025

CEL-SCI CEO Geert R. Kersten Reports Acquisition of Common Shares

Reuters
·
Dec 05, 2025

Financial Morning Brief: PBOC Releases Latest Data! October Social Financing Stock Up 8.5% YoY, China Makes Breakthrough in 6G Technology | November 14, 2025

Deep News
·
Nov 14, 2025

Key Financial News Highlights for November 14, 2025

Deep News
·
Nov 14, 2025

CEL-SCI files to sell 375,000 shares of common stock for holders

TIPRANKS
·
Nov 08, 2025

Trident CTO to Share Customer Impact Insights at Tencent Cloud Day Singapore 2025

GlobeNewswire
·
Nov 06, 2025

Press Release: GERDAU S.A. - CONSOLIDATED INFORMATION

Dow Jones
·
Oct 31, 2025

CEL-SCI Corporation to Present at LD Micro "Main Event" Investor Conference

Reuters
·
Oct 20, 2025

Half-Yearly Results

GlobeNewswire
·
Oct 14, 2025

CELSCI Corporation to Present at LD Micro Main Event Investor Conference

Reuters
·
Oct 10, 2025

Positive Buy Rating for Palvella Therapeutics Driven by Promising CVM Treatment and Market Potential

TIPRANKS
·
Oct 09, 2025

Acoramidis Begins to Reduce Cumulative Cardiovascular Outcomes Within the First Month of Treatment in Patients with ATTR-CM

GlobeNewswire
·
Sep 28, 2025

Sheyang County Accelerates High-Quality Development Through Multi-Dimensional Growth Strategy

Deep News
·
Sep 18, 2025